TickerFacts.

Repligen Corp (RGEN): Total Assets

Annual figures by period end, from SEC filings.

$2.95B
As of 2025-12-31
$2.95B
As of 2026-06-30
+5.2%
3-year compound annual growth
+9.2%
5-year compound annual growth
+35.0%
10-year compound annual growth
2011-03-31: $72.29M2011-12-31: $76.06M2012-12-31: $97.01M2013-12-31: $118.64M2014-12-31: $128.29M2015-12-31: $146.24M2016-12-31: $288.91M2017-12-31: $743.52M2018-12-31: $774.62M2019-12-31: $1.40B2020-12-31: $1.90B2021-12-31: $2.36B2022-12-31: $2.53B2023-12-31: $2.83B2024-12-31: $2.83B2025-12-31: $2.95B$2.95B
2011-03-31 Total Assets (USD) 2025-12-31
Period endedTotal AssetsChange YoYSource filing
2025-12-31$2.95B+4.2%2026-02-26, Balance as of period end
2024-12-31$2.83B-0.1%2026-02-26, Balance as of period end
2023-12-31$2.83B+11.8%2025-03-14, Balance as of period end
2022-12-31$2.53B+7.3%2024-11-18, Balance as of period end
2021-12-31$2.36B+23.9%2023-02-22, Balance as of period end
2020-12-31$1.90B+35.9%2022-02-17, Balance as of period end
2019-12-31$1.40B+80.7%2021-02-24, Balance as of period end
2018-12-31$774.62M+4.2%2020-02-26, Balance as of period end
2017-12-31$743.52M+157.4%2019-03-01, Balance as of period end
2016-12-31$288.91M+97.6%2018-02-22, Balance as of period end
2015-12-31$146.24M+14.0%2017-02-23, Balance as of period end
2014-12-31$128.29M+8.1%2016-02-25, Balance as of period end
2013-12-31$118.64M+22.3%2015-03-17, Balance as of period end
2012-12-31$97.01M+27.5%2014-03-14, Balance as of period end
2011-12-31$76.06Mn/a2013-03-15, Balance as of period end
2011-03-31$72.29Mn/a2012-03-15, Balance as of period end

Total Assets at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedTotal AssetsChange YoY
Repligen Corp (RGEN)2025-12-31$2.95B+4.2%
BioCryst Pharmaceuticals Inc (BCRX)2025-12-31$514.16M+4.8%
ADMA Biologics, Inc. (ADMA)2025-12-31$624.24M+27.7%
Novavax Inc (NVAX)2025-12-31$1.18B-24.6%
Tarsus Pharmaceuticals, Inc. (TARS)2025-12-31$562.16M+49.1%
Bio-Techne Corp (TECH)2026-06-30$2.59B+1.1%
Immunocore Holdings plc (IMCR)2025-12-31$1.07B+5.7%
Halozyme Therapeutics, Inc. (HALO)2025-12-31$2.53B+22.4%
Krystal Biotech, Inc. (KRYS)2025-12-31$1.33B+26.3%

Compare RGEN, BCRX, ADMA, NVAX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗